After reading this issue of Clinical Insights^® in Leg Disorders, participants should be able to:

• Identify the clinical manifestations of peripheral arterial disease (PAD), including possible asymptomatic presentation, and discuss strategies for the concomitant treatment of PAD and underlying disease
• Differentiate rheumatoid arthritis (RA) from other leg disorders that may present with similar symptomology and cite evidence-based pharmacologic and nonpharmacologic approaches for the treatment and management of RA, taking efficacy and safety into consideration
• Discuss the challenges inherent to managing nocturnal leg cramps (NLC) and the limitations of available therapeutic options to effectively treat recurring, severe NLC
• Explore the link between restless legs syndrome, cardiovascular disease, and stroke

This issue of the newsletter is certified for CE credit. After reading this issue of Clinical Insights^® in Leg Disorders, participants should be able to:

• Discuss the overall prevalence of leg disorders as a means to differentiate the more common from the less common and to gain an appreciation for how these disorders impact the health and well-being of patients
• Explain the importance of the accurate assessment of leg disorder symptoms and the necessity for monitoring the prescribed treatment options
• Recognize and counsel patients on the management of leg disorders, including their comorbidities, as well as the side effects and contraindications of available treatment options

• Recognize the clinical manifestations of restless legs syndrome (RLS) and identify methods to overcome barriers to diagnosis
• Differentiate RLS from other leg disorders—nocturnal leg cramps, periodic limb movement disorder, and peripheral neuropathies, among others—that may present with similar symptoms
• Identify the clinical manifestations of diabetic peripheral neuropathy (DPN), differentiating it from other leg disorders
• Describe evidence-based pharmacologic and nonpharmacologic approaches for treating and managing DPN, taking efficacy and safety into consideration